Sign in

    Mattias Häggblom

    Research Analyst at Handelsbanken

    Mattias Häggblom is an Equity Research Analyst and Sector Head for Life Science at Handelsbanken, specializing in health care and life science sector research, with coverage focused on companies including Demant A/S, WILLF, and ALIF.B. His investment calls have achieved a 50% success rate over the last year, although his average return per rating currently stands at -2.8%, with notable profitability shown in specific short trades such as a +17.9% return on WILLF. Häggblom joined Handelsbanken in 2007 and has led coverage of major Nordic and UK/US market players, building a reputation for incisive life science insights after early career experience in financial research. He is recognized for his in-depth sector expertise and is a publicly listed analyst on platforms such as TipRanks, with credentials available through Handelsbanken and industry media, although FINRA or specific securities licenses are not independently listed.

    Mattias Häggblom's questions to ASTRAZENECA (AZN) leadership

    Mattias Häggblom's questions to ASTRAZENECA (AZN) leadership • Q1 2025

    Question

    Mattias Häggblom asked about the likelihood of the pharmaceutical industry uniting its messaging on pricing and tariffs, and inquired where AstraZeneca's internal models might deviate from consensus regarding its $80 billion revenue target for 2030.

    Answer

    CEO Pascal Soriot expressed his belief that the industry is coming together to address tariffs and the innovation funding imbalance between the U.S. and Europe. CFO Aradhana Sarin suggested that areas of potential upside versus consensus for the 2030 target include the biopharma and rare disease portfolios (e.g., respiratory, CVRM, oral PCSK9) and the company's proprietary ADC and cell therapy pipelines, which may not be fully valued by the market.

    Ask Fintool Equity Research AI

    Mattias Häggblom's questions to ASTRAZENECA (AZN) leadership • Q4 2024

    Question

    Mattias Häggblom of Handelsbanken inquired about the oral GLP-1 program's trial duration relative to FDA guidance and the oral PCSK9 inhibitor, asking for expectations for upcoming data, Phase III timelines, and its competitive positioning against Merck's asset.

    Answer

    Sharon Barr, EVP of BioPharmaceuticals R&D, expressed confidence in the ongoing oral GLP-1 trials, which are enrolling well. For the oral PCSK9, she anticipates the upcoming Phase IIb data will be broadly in line with strong Phase I results. She highlighted its differentiation as a true small molecule with no food effect, making it suitable for combinations. CEO Pascal Soriot added that having two companies in the oral PCSK9 market will help expand access globally.

    Ask Fintool Equity Research AI

    Mattias Häggblom's questions to ASTRAZENECA (AZN) leadership • Q2 2024

    Question

    Mattias Häggblom asked if the Inflation Reduction Act (IRA) has led AstraZeneca to cancel or alter development plans for small molecule assets and how it has impacted business development strategy.

    Answer

    CEO Pascal Soriot acknowledged the IRA challenges small molecules but noted the company's strategic shift towards biologics was already underway. He explained the main impact is that for certain small molecules, the company may have to delay U.S. filings for initial, smaller indications to avoid starting the nine-year negotiation clock prematurely, an issue they are advocating to fix.

    Ask Fintool Equity Research AI

    Mattias Häggblom's questions to GNNDY leadership

    Mattias Häggblom's questions to GNNDY leadership • Q1 2024

    Question

    Asked if the DKK 600 million savings target could be conservative given the strong start, and why the full-year free cash flow outlook wasn't raised after a significant Q1 beat.

    Answer

    The company is committed to the DKK 600 million synergy target for now and will reassess after crossing the DKK 400 million milestone for this year. For cash flow, the guidance remains 'more than DKK 700 million,' and while Q1 was a positive start that supports this outlook, the formal guidance is not being changed at this time.

    Ask Fintool Equity Research AI

    Mattias Häggblom's questions to GNNDY leadership • Q3 2023

    Question

    Asked for a precise definition of 'midterm' for GN Audio's 20%+ margin target, given consensus estimates for 2026 are lower. He also inquired about expectations for working capital release and cash generation in Q4.

    Answer

    The company has not set an exact date for the 'midterm' Audio margin target, stating it depends on the market returning to structural growth rates. For Q4, they anticipate a positive cash flow supported by DKK 200-300 million in inventory reductions and a release from high receivables at the end of Q3.

    Ask Fintool Equity Research AI